cystic fibrosis Archives

News and Trends 6 Aug 2018

New Gene Therapy Could Treat Cystic Fibrosis With One Dose

A new partnership in the UK will develop a gene therapy for cystic fibrosis that could treat the disease with a single dose. Cystic fibrosis is a genetic disease that causes mucus to build up in a patient’s lungs. As a result, patients suffer from blocked airways and bacterial infections. While treatment advances have increased […]

August 6, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 12 Apr 2018

British Biotech Raises £29M Round to Fight Lung Disease

Enterprise Therapeutics has raised a substantial Series B financing round to bring its treatments for respiratory diseases into clinical development. Enterprise Therapeutics, a British biotech, has raised £29M (€33M) in Series B from several investors including Forbion, one of the most active European life science VCs. In Enterprise, Forbion has found a replacement in its portfolio for the Dutch […]

April 12, 2018 - 2 minutesmins - By Alexander Burik

Interview 12 Mar 2018

A Dutch Company on the Quest Against Cystic Fibrosis

ProQR is the result of a personal quest against cystic fibrosis started by its CEO, Daniel de Boer. Interested in his story and the company’s unique approach to treating the disease using RNA technology, I decided to speak with him. Daniel de Boer founded ProQR in 2012 following a strong determination to improve the lives […]

March 12, 2018 - 6 minutesmins - By Clara Rodríguez Fernández

News and Trends 2 Mar 2018

London Biotech Uses Unique Double Mechanism of Action to Treat Cystic Fibrosis

Verona Pharma obtained positive Phase IIa trial results for a unique cystic fibrosis drug that inhibits two disease-related enzymes simultaneously, showing promise for treating a high unmet patient need. Verona Pharma, based in London, UK, aims to improve the lives of people with chronic respiratory diseases. Verona states their Phase IIa data provide grounds to […]

March 2, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 14 Dec 2017

A Breath of Fresh Air for Biotechs Working on Cystic Fibrosis Therapies?

Researchers from the University of Zurich have determined the structure of a chloride channel, which could be a target for new drugs to treat cystic fibrosis. Researchers at the University of Zurich have found a new target for future cystic fibrosis treatments. The study, published in Nature, has uncovered the structure of a protein that could help to […]

December 14, 2017 - 3 minutesmins - By Alex Dale

News and Trends 22 Nov 2017

Galapagos Cystic Fibrosis Drug Enters Phase I, Triggering €8.5M Payout

Galapagos will receive a $10M (€8.5M) milestone payment from its collaborator, AbbVie, after their cystic fibrosis candidate started a Phase I trial. Galapagos is a clinical-stage biotech developing small molecule medicines for a range of indications. It partnered up with the global pharma company, AbbVie, back in 2013, to develop a number of cystic fibrosis (CF) candidates for a […]

November 22, 2017 - 3 minutesmins - By Alex Dale

News and Trends 14 Nov 2017

Dutch RNA Firm Announces a Public Offering when its Stock is at an All-Time Low

ProQR is aiming to raise funds for clinical trials on the Nasdaq despite the fact that its stock has been down for a while now. ProQR is a biotech based in Leiden that develops RNA therapies for genetic disorders, with its lead program focused on cystic fibrosis. In order to fund clinical trials, research and […]

November 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 26 Jul 2017

Update: Potential Breakthrough Treatment for Deadly Lung Disease Starts Phase IIb

Update (26/07/2017): Verona Pharma has dosed the first patients in the PhaseIIb with RPL554 in patients with chronic obstructive pulmonary disease (COPD). Results are expected in the second half of 2018. Published on 27/06/2017 Verona Pharma has secured regulatory approval in five European countries to run a Phase IIb trial with its dual PDE3/4 inhibitor in […]

July 26, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 19 Apr 2017

UPDATE: Verona sets terms & dials back its IPO goal to a still-hefty €75M

UPDATE: Verona set the terms for its US IPO yesterday and knocked $10M (€9.3M) off its target, now shooting for $75M (€70M). The public shares are expected to hit the NASDAQ exchange next week. Original Publication 04/04/2017 British Verona Pharma has filed for an IPO on Nasdaq to raise up to €81M ($86M). The funds should be […]

April 19, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 12 Apr 2017

Swiss Pharma Clears €37M Funding to Develop a New Class of Antibiotics

Swiss Polyphor has closed a €37M (CHF40M) private funding round to finance the development of its most advanced candidate tackling antibiotic resistances. Polyphor is a clinical stage pharma developing a specific class of so called ‘macrocyclic drugs‘, which are chemically defined by a ring structure. The company’s pipeline is covering a broad range of diseases such as […]

April 12, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 23 Mar 2017

Galapagos Enters Clinical Trials with New Cystic Fibrosis Drug

Galapagos has announced to kick off a Phase I trial with its novel Cystic Fibrosis potentiator GLPG3067, triggering a €7M milestone payment from AbbVie. Galapagos and AbbVie teamed up in 2013, with the aim of developing a triple combination therapy for the treatment of Cystic Fibrosis (CF). Now, Galapagos announced the start of a Phase […]

March 23, 2017 - 2 minutesmins - By Melanie De Almeida

More News! 2 Feb 2017

Galapagos kicks off a Phase IIa trial for Cystic Fibrosis

After Galapagos and AbbVie expanded their collaboration on cystic fibrosis, Galapagos now announces the start of their Phase IIa trial for a novel cystic fibrosis corrector. Since entering their collaboration with AbbVie on cystic fibrosis (CF) in 2013, Galapagos has received almost €40M in milestone payments from AbbVie. Galapagos now announced the start of a Phase […]

February 2, 2017 - 2 minutesmins - By Melanie De Almeida

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us